Merck Prepares for Keytruda Loss While Fiverr Cuts Costs to Tap Freelance Market Potential
• Merck relies heavily on cancer drug Keytruda, but it will lose patent protection in 2028; the company is preparing for this with new potential blockbuster therapies like sotatercept and MK-0616.
• Merck pays a decent dividend that has grown 40% in 5 years; reinvesting dividends can lead to great returns over the next decade.
• Fiverr is a top freelance services marketplace, but growth has slowed significantly from pandemic highs.
• Fiverr has cut costs to become profitable, which boosted its stock price recently.
• Fiverr has huge long-term potential as the freelance/gig economy grows; it targets a $247 billion addressable market and only needs a small chunk to drive big growth.